Samuel C. Blackman
CIK 1863676 · HEAD OF R&D · last filed 2024-12-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DAWN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 217
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals, Inc. (DAWN) Delisted | HEAD OF R&D | 2,034,015 | $21.53 | $43.79M | -$6.62M | 38 | 2024-12-12 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| DAWN | Direct | 1,034,015 | 50.8% | 2024-12-12 |
| See footnote | 1,000,000 | 49.2% | 2024-12-12 | |
| Total | 2,034,015 | |||
| No longer reported | ||||
| By the 2021 Blackman Family LLC | 1,000,000 | — | last 2023-06-07 | |
Recent Filings · Page 2 of 5
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-16 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) Officer · Planned Aug 16, 2024 Sold: Form 4 filed Aug 19, 2024 |
−2,232 | -$31.2K | EDGAR |
| 2024-07-17 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Sell (S)10b5-1 Plan adopted Oct 10, 2023 |
−20,000 | -$320.2K | EDGAR |
| 2024-07-16 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) Officer · Planned Jul 16, 2024 · 10b5-1 plan Sold: Form 4 filed Jul 17, 2024 |
−80,000 | -$1.26M | EDGAR |
| 2024-06-12 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Sell (S)10b5-1 Plan adopted Oct 10, 2023 |
−30,000 | -$378.6K | EDGAR |
| 2024-06-10 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) Officer · Planned Jun 10, 2024 · 10b5-1 plan Sold: Form 4 filed Jun 12, 2024 |
−30,000 | -$383.1K | EDGAR |
| 2024-05-17 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Mixed | +6,419 | -$36.5K | EDGAR |
| 2024-05-16 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Notice (144) Officer · Planned May 16, 2024 Sold: Form 4 filed May 17, 2024 |
−2,267 | -$36.5K | EDGAR |
| 2024-05-14 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Sell (S)10b5-1 Plan adopted Oct 10, 2023 |
−10,000 | -$163.7K | EDGAR |
| 2024-04-22 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Sell (S)10b5-1 Plan adopted Oct 10, 2023 |
−10,000 | -$160.2K | EDGAR |
| 2024-03-26 | Day One Biopharmaceuticals, Inc. (DAWN) Delisted | Sell (S)10b5-1 Plan adopted Oct 10, 2023 |
−10,000 | -$160.1K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).